10. Bruker (Nasdaq:BRKR): +62.0%
Bruker – the Billerica, Mass.–based provider of high-performance scientific instruments and high-value analytical and diagnostic – saw its third-quarter revenues increase 10.6% year-over-year, to nearly $436 million. Sales for the first nine months of the year were up 8.3%, to $1.2 billion.
“This growth reflects improvements in our academic markets, particularly in Europe, and in global industrial markets, as well as contributions from our targeted growth areas,” Bruker CEO Frank Laukien said in a news release. “In the first nine months of 2017, Bruker’s operating profit has increased at double-digit rates on both a GAAP and non-GAAP basis, while year-over-year EPS comparisons were adversely affected by an unusually low 2016 tax rate, as expected.”
Bruker in November upped its revenue growth forecast to 8–8.5%. This month, it made a play to expand its microbiology assay through its acquisition of InVivo Biotech Services (Hennigsdorf, Germany).